We support preclinical drug discovery by creating opportunities to screen in human disease-relevant platforms before or after animal studies. We explore the effects of drugs in preserving or improving the function and survival of iPSC-derived cells, such as cardiomyocytes, using strategies that could lead to "clinical trials in a dish," even down to the level of individual patients.
Shortening development times and assuring translatability by using human disease-relevant platforms.
Enabling exploration of therapeutic strategies tailored to individual patients.
We offer pharmaceutical companies innovative ways to improve the preclinical phases of drug development. By utilizing human disease-relevant platforms, we can conduct screenings before or after animal studies, enhancing the predictive value of preclinical testing and facilitating the development of personalized treatments.
Our human-based platforms assure better translatability to clinical outcomes.
Shortening development times by providing early human-relevant data.
.jpg)
We provide a suite of services designed to forecast therapeutic efficacy and safety using advanced human-relevant models.
We employ resonance energy transfer-based biosensors to interrogate large sections of the signaling signatures of specific G protein–coupled receptors (GPCRs). Our biosensor platform is available in adeno-associated viral formats for use in iPSC-derived cells. Using these biosensors, we determine which signaling pathways are modulated by dose-dependent activation of individual receptors, aiding in compound validation and new lead discovery.
By modeling disease progression in iPSC-derived cells, we can track therapeutic progression and explore the effects of drugs on preserving or improving cell function and survival. This approach allows for testing therapeutic strategies that might work better in specific patients—validated in clinical studies of cardiomyopathy patients.
We offer services for imaging-based drug discovery across various cellular venues. Our advanced imaging technologies enable detailed analysis of drug effects on cellular functions, providing valuable insights for therapeutic development.
Our predictive services empower researchers and pharmaceutical companies to make informed decisions early in the drug development process, enhancing the likelihood of clinical success.
Human-relevant models improve the predictive accuracy of preclinical testing.
Facilitates the development of treatments tailored to individual patient profiles.
Contact us today to discover how we can support your innovative work with personalized solutions.
